Ambey Laboratories Limited (NSE:DHANSA)
India · Delayed Price · Currency is INR 25.00
0.00 (0.00%)
At close: May 29, 2026
Ambey Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,415 | 1,313 | 1,205 | 1,048 | 846.01 |
Other Revenue | 13.1 | 16.31 | 14.6 | 26.57 | 3.04 |
Revenue | 1,428 | 1,329 | 1,219 | 1,075 | 849.05 |
Revenue Growth (YoY) | 7.48% | 9.00% | 13.45% | 26.59% | 3.39% |
Cost of Revenue | 1,264 | 1,172 | 1,068 | 909.12 | 688.97 |
Gross Profit | 164.41 | 157.28 | 150.97 | 165.66 | 160.08 |
Selling, General & Admin | 11.58 | 28.7 | 28.08 | 35.61 | 29.98 |
Other Operating Expenses | 30.65 | 16.42 | 17.57 | 25.27 | 23.65 |
Operating Expenses | 64.21 | 70.55 | 70.8 | 90.5 | 83.33 |
Operating Income | 100.2 | 86.72 | 80.17 | 75.16 | 76.75 |
Interest Expense | -26.24 | -27.68 | -23.1 | -19.46 | -30.51 |
Interest & Investment Income | - | 1.5 | 0.1 | 0.06 | 0.06 |
Currency Exchange Gain (Loss) | - | 0.24 | 1.16 | 1.03 | 2.02 |
Other Non Operating Income (Expenses) | - | -1.43 | -1.04 | -1.15 | - |
EBT Excluding Unusual Items | 73.96 | 59.35 | 57.28 | 55.64 | 48.31 |
Gain (Loss) on Sale of Investments | - | 1.11 | - | - | - |
Gain (Loss) on Sale of Assets | - | -0.07 | - | - | - |
Other Unusual Items | - | - | -2.97 | -0.61 | - |
Pretax Income | 73.96 | 60.38 | 54.32 | 55.03 | 48.31 |
Income Tax Expense | 18.74 | 12.56 | -22.9 | 2.63 | 12.56 |
Net Income | 55.23 | 47.83 | 77.22 | 52.4 | 35.75 |
Net Income to Common | 55.23 | 47.83 | 77.22 | 52.4 | 35.75 |
Net Income Growth | 15.47% | -38.06% | 47.36% | 46.59% | -65.42% |
Shares Outstanding (Basic) | 25 | 23 | 18 | 18 | 5 |
Shares Outstanding (Diluted) | 25 | 23 | 18 | 18 | 5 |
Shares Change (YoY) | 7.48% | 27.87% | 2.44% | 251.74% | 3.12% |
EPS (Basic) | 2.21 | 2.06 | 4.25 | 2.95 | 7.08 |
EPS (Diluted) | 2.21 | 2.06 | 4.25 | 2.95 | 7.08 |
EPS Growth | 7.43% | -51.56% | 43.96% | -58.36% | -66.46% |
Free Cash Flow | -536.46 | -480.01 | -182.57 | 69.61 | 48.48 |
Free Cash Flow Per Share | -21.47 | -20.65 | -10.04 | 3.92 | 9.61 |
Gross Margin | 11.51% | 11.83% | 12.38% | 15.41% | 18.85% |
Operating Margin | 7.02% | 6.53% | 6.58% | 6.99% | 9.04% |
Profit Margin | 3.87% | 3.60% | 6.33% | 4.88% | 4.21% |
Free Cash Flow Margin | -37.55% | -36.12% | -14.97% | 6.48% | 5.71% |
EBITDA | 122.18 | 110.33 | 102.92 | 102.34 | 103.45 |
EBITDA Margin | 8.55% | 8.30% | 8.44% | 9.52% | 12.18% |
D&A For EBITDA | 21.98 | 23.61 | 22.75 | 27.19 | 26.7 |
EBIT | 100.2 | 86.72 | 80.17 | 75.16 | 76.75 |
EBIT Margin | 7.02% | 6.53% | 6.58% | 6.99% | 9.04% |
Effective Tax Rate | 25.33% | 20.79% | - | 4.77% | 26.00% |
Revenue as Reported | 1,428 | 1,332 | 1,221 | 1,076 | 851.12 |
Advertising Expenses | - | 1.04 | 1.44 | 2.87 | 2.13 |